A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
14
Participants
Timeline
Start Date
September 30, 2012
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Conditions
Pharmacokinetics of ASP3652Pharmacodynamics of ASP3652Healthy Subjects
Interventions
DRUG
ASP3652
oral
Trial Locations (1)
HA1 3UJ
PAREXEL Early Phase Clinical Unit, Harrow
All Listed Sponsors
lead
Astellas Pharma Europe B.V.
INDUSTRY
NCT02034734 - A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects | Biotech Hunter | Biotech Hunter